Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
845 stopped studies mapped to Malignant Bone Marrow Neoplasm and descendants · 88% state a reason
Over the 845 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk… | Phase 1 / Phase 2 | terminated | Jun 1, 2007 | M.D. Anderson Cancer Center | Lack of support. | Other (stated, no rule matched) |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | — | terminated | Mar 5, 2007 | M.D. Anderson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT00513305 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients… | Phase 3 | terminated | Aug 8, 2007 | Cephalon | Study has been stopped by sponsor decision | Sponsor / business decision |
| NCT00960726 | NOV-002 in Myelodysplastic Syndrome (MDS) | Phase 2 | withdrawn | Aug 18, 2009 | M.D. Anderson Cancer Center | Study withdrawn at sponsor request. | Other (stated, no rule matched) |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | Phase 3 | terminated | Jul 20, 2012 | Consorzio Mario Negri Sud | Low accrual rate not allowing planned sample size leads to a futility condition | Efficacy / futility |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | Phase 2 | terminated | May 6, 2009 | M.D. Anderson Cancer Center | The trial was ended per sponsor due to slow accrual rates. | Enrollment / accrual |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00886496 | Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL… | Phase 1 | withdrawn | Apr 23, 2009 | Enzon Pharmaceuticals, Inc. | No participants enrolled. IND withdrawn. | Enrollment / accrual |
| NCT00253552 | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders | N/A | terminated | Nov 15, 2005 | OHSU Knight Cancer Institute | Terminated at request of PI as study was outdated. | Other (stated, no rule matched) |
| NCT00570999 | Palifermin After Haploidentical PBSCT(KGF Haplo Allo) | Phase 2 | withdrawn | Dec 11, 2007 | European Society for Blood and Marrow Transplantation | not stated | Not stated |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte… | Phase 2 | terminated | Jan 22, 2009 | Northside Hospital, Inc. | Unacceptable morbidity \& mortality | Other (stated, no rule matched) |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and… | Phase 1 | terminated | Feb 10, 2010 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01546337 | Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid…(EPO) | — | terminated | Mar 7, 2012 | Rennes University Hospital | not stated | Not stated |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | Phase 1 | withdrawn | Oct 14, 2011 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic… | Phase 1 | terminated | Dec 23, 2003 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | Phase 2 | terminated | Mar 12, 2007 | Groupe Francophone des Myelodysplasies | not stated | Not stated |
| NCT00245128 | Imatinib Mesylate in Treating Patients With Myelofibrosis | Phase 2 | terminated | Oct 27, 2005 | OHSU Knight Cancer Institute | Per PI, results from another similar study were published prior to study analysis. Negative study… | Other (stated, no rule matched) |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | Phase 2 | terminated | May 8, 2009 | European Society for Blood and Marrow Transplantation | Slow recruitment. No safety concerns during this study. | Safety / toxicity |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous…(ENEST) | Phase 3 | terminated | Aug 21, 2007 | Novartis Pharmaceuticals | This study was terminated due to limited enrollment. | Enrollment / accrual |
| NCT01011998 | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | Phase 2 | withdrawn | Nov 11, 2009 | New Mexico Cancer Research Alliance | Withdrawn due to lack of accrual per Center DSMP, with PI concurrence | Enrollment / accrual |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | Phase 1 | terminated | Feb 1, 2007 | Callisto Pharmaceuticals | Participants are no longer being examined or treated. | Other (stated, no rule matched) |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients…(FB-ATG) | Phase 2 | terminated | Jun 8, 2009 | King's College Hospital NHS Trust | FB ATG is now a standard for sib allo MDS patients | Other (stated, no rule matched) |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Feb 9, 2009 | University of Ulm | Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six… | Efficacy / futility |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Sep 13, 2005 | Hadassah Medical Organization | PI is no longer work at Hadassah | Other (stated, no rule matched) |
| NCT00381693 | Azacitidine in Treating Patients With Myelofibrosis | Phase 2 | terminated | Sep 28, 2006 | Mayo Clinic | Due to lack of accrual and trial has demonstrated too little clinical benefit | Enrollment / accrual |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | Phase 2 | terminated | Sep 18, 2007 | Columbia University | Poor accrual | Enrollment / accrual |
| NCT00226512 | To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to… | Phase 3 | withdrawn | Sep 27, 2005 | Hadassah Medical Organization | the PI is no longer work at Hadassah | Other (stated, no rule matched) |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | Phase 1 | terminated | Aug 29, 2007 | Exelixis | Due to emerging safety data | Safety / toxicity |
| NCT00813501 | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a… | — | terminated | Dec 23, 2008 | City of Hope Medical Center | Terminated at the request of the study sponsor | Other (stated, no rule matched) |
| NCT01034410 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary… | Phase 2 | terminated | Dec 17, 2009 | Antisoma Research | not stated | Not stated |
| NCT00486265 | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics… | Phase 1 | terminated | Jun 14, 2007 | AstraZeneca | AML assess. of response in Part B patients find treatment failure in all 8 evaluable for marrow… | Other (stated, no rule matched) |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid… | Phase 1 | terminated | Jan 20, 2006 | Novartis Pharmaceuticals | Study was stopped due to time dependent drug accumulation | Other (stated, no rule matched) |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | Phase 2 | terminated | May 8, 2006 | Symphony Evolution, Inc. | Study was terminated due to cardiac toxicities | Safety / toxicity |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone… | Phase 1 | terminated | Jan 27, 2003 | University of Medicine and Dentistry of New Jersey | At this time it is felt that we will not gain further information from an additional patients. | Other (stated, no rule matched) |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | Phase 3 | terminated | Mar 23, 2006 | Radboud University Medical Center | Interim analysis has shown that the objectives of this study can not be reached | Efficacy / futility |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in… | Phase 1 | terminated | Oct 15, 2007 | Sanofi | due to absence of evidence of clinical activity up to toxic doses | Other (stated, no rule matched) |
| NCT00461929 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on…(GIST) | Phase 4 | terminated | Apr 18, 2007 | University Health Network, Toronto | study terminated 12Feb09 due to low recruitment | Enrollment / accrual |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute… | Phase 2 | withdrawn | Jan 15, 2008 | University of Cincinnati | Principal Investigator resigned position with the University of Cincinnati, closing study at this… | Investigator |
| NCT00363025 | A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous… | Phase 3 | terminated | Aug 15, 2006 | Acute Leukemia French Association | not stated | Not stated |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute… | Phase 1 / Phase 2 | terminated | Mar 1, 2005 | SGX Pharmaceuticals, Inc. | Trial stopped June 2007 | Other (stated, no rule matched) |
| NCT00511121 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human… | Phase 2 | terminated | Aug 3, 2007 | University of Bologna | not stated | Not stated |
| NCT00126893 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid… | Phase 1 | terminated | Aug 5, 2005 | Celgene Corporation | not stated | Not stated |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | Phase 2 | terminated | Sep 2, 2005 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | Phase 2 | suspended | May 24, 2006 | Samsung Medical Center | not stated | Not stated |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute… | Phase 1 / Phase 2 | terminated | Sep 22, 2005 | Poitiers University Hospital | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 7, 2012source: clinicaltrials